CN105030807A - Application of nicotinamide riboside to preparing medicine for treating cerebral ischemic diseases - Google Patents
Application of nicotinamide riboside to preparing medicine for treating cerebral ischemic diseases Download PDFInfo
- Publication number
- CN105030807A CN105030807A CN201510406371.4A CN201510406371A CN105030807A CN 105030807 A CN105030807 A CN 105030807A CN 201510406371 A CN201510406371 A CN 201510406371A CN 105030807 A CN105030807 A CN 105030807A
- Authority
- CN
- China
- Prior art keywords
- cerebral
- application
- nicotinamide riboside
- nicotiamide
- ribose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to application of nicotinamide riboside to preparing medicine for treating cerebral ischemic diseases. The application has the advantages that influence of the nicotinamide riboside on cerebral infarction areas of cerebral ischemic models formed in the brains of rats due to artery electrocoagulation occlusion is studied, the cerebral infarction areas can be obviously reduced by nicotinamide riboside administration as proved by the study, obvious cerebral ischemic protection effects can be realized by the nicotinamide riboside as shown by the study, brain injury due to cerebral ischemia can be prevented and treated, and accordingly the nicotinamide riboside has a broad application prospect in the aspects of preparing related medicine for cerebral ischemic injury and/or cerebral infarction.
Description
Technical field
The present invention relates to the novelty teabag of compound, specifically, relate to the application of nicotiamide ribose in preparation treatment Imaging in Patients with Cerebral Ischemia Disease medicine.
Background technology
Nicotiamide ribose is a kind of ucleotides compound, and No. CAS is 1341-23-7, and structural formula is:
Existing external report finds that nicotiamide ribose has protective effect in obesity, hearing impairment, senile neurological degeneration are as diseases such as alzheimer's disease (AD), parkinson (PD), can improve cognitive decline.Chinese patent literature CN201510098227.9, publication date 2015.05.20, disclose the application of nicotiamide ribose in the medicine of preparation treatment non-alcoholic stellato-hepatitis, by non-alcoholic stellato-hepatitis animal model, confirm that nicotiamide ribose can reduce the liver lipids content of animal model, inflammation and degree of hepatic fibrosis, prompting nicotiamide ribose can be used for the medicine preparing treatment non-alcoholic stellato-hepatitis.
But, there is no the bibliographical information of nicotiamide ribose to the protective effect of cerebral ischemia at present.
Summary of the invention
The object of the invention is, for deficiency of the prior art, to provide the novelty teabag of nicotiamide ribose.
In a first aspect of the present invention, provide the application of nicotiamide ribose in the medicine of preparation control cerebral ischemia.
As a kind of detailed description of the invention of the present invention, described control cerebral ischemia refers to minimizing brain infarction area.
In a second aspect of the present invention, provide nicotiamide ribose and preparing the application in medicine, described medicine is for reducing the brain infarction area of cerebral ischemia.
In a third aspect of the present invention, provide the application of nicotiamide ribose in the medicine of preparation control cerebral infarction.
Herein, described nicotiamide ribose structural formula is:
Herein, described " cerebral ischemia " refers to the intracranial vessel pathological changes comprising TIA, cerebral infarction and moyamoya (but being not limited only to this), and its main pathology caused is changed to cerebral ischemia infringement.Generally speaking, described " cerebral ischemia " may be caused by following reason: the 1. inside and outside stricture of artery of cranium or obturation; 2. cerebral embolism; 3. Hemodynamic Factors; 4. hematologic agent etc.The main cause of cerebral arterial stenosis or obturation is caused to be atherosclerosis.Cause the main cause of cerebral embolism to comprise atherosclerosis, and the embolus formed because suffering from rheumatic valvular heart disease, subacute bacterial endocarditis, congenital heart disease, artificial valve and operation on heart etc. enter the thromboembolism caused in brain with blood flow.Hemodynamic Factors comprises the cerebral ischemia that of short duration hypotension causes, such as myocardial infarction, severe arrhythmia, shock, carotid sinus hypersensitivity, orthostatic hypotension, subclavian steal syndrome etc.Hematologic agent comprises the high blood coagulation state that oral contraceptive, gestation, puerpera, Post operation and thrombocytosis cause, and the stickiness that erythrocytosis, sicklemia, macroglobulinemia cause increases caused cerebral ischemia.
The invention has the advantages that: the present invention is by the impact of research nicotiamide ribose on the brain infarction area of the cerebral ischemic model in the formation of intraluminal middle cerebral artery occlusion in rats coagulation obstruction; confirm that nicotiamide ribose administration obviously can reduce brain infarction area; show that nicotiamide ribose has significant Cerebral ischemia protection effect; the brain injury that cerebral ischemia causes can be prevented and treated, have broad application prospects preparing in cerebral ischemia and/or cerebral infarction related drugs.The present invention is that cerebral ischemia provides new medicament research and development direction.
Accompanying drawing explanation
Fig. 1 .TTC dyes representative picture.
Detailed description of the invention
Below in conjunction with accompanying drawing, detailed description of the invention provided by the invention is elaborated.
Embodiment 1
One, method
Permanent cerebral ischemia damage model is prepared with rat (Sprague-Dawley rat, about body weight 250g, Shanghai Slac Experimental Animal Co., Ltd.).Process is as follows: by rat anesthesia, opens skull, directly visual lower to middle cerebral artery coagulation, causes left side middle cerebral artery blocking.Rats by intraperitoneal injection nicotiamide ribose (30mg/kg is purchased from Han Xiang bio tech ltd, Shanghai) is given after 30 minutes.The normal saline that matched group gives 0.9% gives lumbar injection.Reset skull, skin suture, namely successfully prepares intraluminal middle cerebral artery occlusion in rats and blocks the permanent cerebral ischemia model caused.Latter 24 hours of middle cerebral artery blocking, gives to detect brain infarction area.Cerebral infarction volume detects employing 2,3,5-triphenyltetrazolium chloride (purchased from Amersco company) staining, i.e. TTC staining.
Two, result
Fig. 1 is shown in by the TTC representative picture that dyes, and cerebral infarction volume statistical result is in table 1.Result shows: nicotiamide ribose significantly reduces the brain infarction area (P<0.001) of rat, and showing it can to anti-cerebral ischemia damnification.
Table 1 saline control group and nicotiamide ribose to treat group Brain stem injury (%)
Note: * * * P<0.001vs matched group, N=10.Numeral in form is the percentage ratio that cerebral infarction accounts for full brain scope.
The above is only the preferred embodiment of the present invention; it should be pointed out that for those skilled in the art, under the prerequisite not departing from the inventive method; can also make some improvement and supplement, these improve and supplement and also should be considered as protection scope of the present invention.
Claims (5)
1. the application of nicotiamide ribose in the medicine of preparation control cerebral ischemia.
2. application according to claim 1, is characterized in that, described control cerebral ischemia refers to minimizing brain infarction area.
3. nicotiamide ribose is preparing the application in medicine, it is characterized in that, described medicine is for reducing the brain infarction area of cerebral ischemia.
4. the application of nicotiamide ribose in the medicine of preparation control cerebral infarction.
5., according to the arbitrary described application of claim 1-4, it is characterized in that, described nicotiamide ribose structural formula is:
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510406371.4A CN105030807B (en) | 2015-07-13 | 2015-07-13 | Niacinamide ribose is preparing the application in treating Imaging in Patients with Cerebral Ischemia Disease drug |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510406371.4A CN105030807B (en) | 2015-07-13 | 2015-07-13 | Niacinamide ribose is preparing the application in treating Imaging in Patients with Cerebral Ischemia Disease drug |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN105030807A true CN105030807A (en) | 2015-11-11 |
| CN105030807B CN105030807B (en) | 2018-11-06 |
Family
ID=54438174
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510406371.4A Active CN105030807B (en) | 2015-07-13 | 2015-07-13 | Niacinamide ribose is preparing the application in treating Imaging in Patients with Cerebral Ischemia Disease drug |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105030807B (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107412247A (en) * | 2016-05-23 | 2017-12-01 | 上海风劲生物医药科技有限公司 | Application of the nicotinamide mononucleotide in prevention or treatment cerebral hemorrhage medicine is prepared |
| CN107536844A (en) * | 2017-06-30 | 2018-01-05 | 上海风劲生物医药科技有限公司 | Application of the nicotinamide mononucleotide in the medicine for preparing prevention or treatment rtPA vascular complications |
| WO2021180731A1 (en) * | 2020-03-09 | 2021-09-16 | Société des Produits Nestlé S.A. | Compositions and methods containing reduced nicotinamide riboside for prevention and treatment of cardiovascular diseases and conditions |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101601679A (en) * | 2009-03-17 | 2009-12-16 | 中国人民解放军第二军医大学 | A kind of application of nicotinamide mononucleotide. |
| CN104367587A (en) * | 2013-12-06 | 2015-02-25 | 中国人民解放军第二军医大学 | Application of nicotinamide mononucleotide in preparation of medicines for promotion of nerve regeneration after cerebral ischemia |
-
2015
- 2015-07-13 CN CN201510406371.4A patent/CN105030807B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101601679A (en) * | 2009-03-17 | 2009-12-16 | 中国人民解放军第二军医大学 | A kind of application of nicotinamide mononucleotide. |
| CN104367587A (en) * | 2013-12-06 | 2015-02-25 | 中国人民解放军第二军医大学 | Application of nicotinamide mononucleotide in preparation of medicines for promotion of nerve regeneration after cerebral ischemia |
Non-Patent Citations (3)
| Title |
|---|
| CARLES CANTO等: "The NAD+ Precursor Nicotinamide Riboside Enhances Oxidative Metabolism and Protects against High-Fat Diet-Induced Obesity", 《CELL METABOLISM》 * |
| 殷卫海等: "氧化应激、PARP-1和NAD+在缺血性脑损伤中的作用和机制", 《内科理论与实践》 * |
| 油红捷等: "脂肪因子visfatin的调节与功能多样性", 《生物化学与生物物理进展》 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107412247A (en) * | 2016-05-23 | 2017-12-01 | 上海风劲生物医药科技有限公司 | Application of the nicotinamide mononucleotide in prevention or treatment cerebral hemorrhage medicine is prepared |
| CN107536844A (en) * | 2017-06-30 | 2018-01-05 | 上海风劲生物医药科技有限公司 | Application of the nicotinamide mononucleotide in the medicine for preparing prevention or treatment rtPA vascular complications |
| WO2021180731A1 (en) * | 2020-03-09 | 2021-09-16 | Société des Produits Nestlé S.A. | Compositions and methods containing reduced nicotinamide riboside for prevention and treatment of cardiovascular diseases and conditions |
Also Published As
| Publication number | Publication date |
|---|---|
| CN105030807B (en) | 2018-11-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Ahmed et al. | Angiotensin receptor (AT2R) agonist C21 prevents cognitive decline after permanent stroke in aged animals—A randomized double-blind pre-clinical study | |
| WO2016025745A1 (en) | Dendrimer compositions and use in treatment of neurological and cns disorders | |
| TW201002315A (en) | Anti-tumoural effects of cannabinoid combinations | |
| ES2830447T3 (en) | Method for the prevention and / or treatment of cognitive impairment associated with aging and neuroinflammation | |
| MX2010003774A (en) | Aqueous ophthalmic formulations. | |
| JP2018520189A5 (en) | ||
| MX2020010907A (en) | Enhancement of delivery of lipophilic active agents across the blood-brain barrier and methods for treating central nervous system disorders. | |
| WO2006003488A3 (en) | Annexins, derivatives thereof, and annexin-cys variants, as well as therapeutic and diagnostic uses thereof | |
| CN105030807A (en) | Application of nicotinamide riboside to preparing medicine for treating cerebral ischemic diseases | |
| JP2014526541A5 (en) | ||
| Xu et al. | Engineering a pathological tau-targeted nanochaperone for selective and synergetic inhibition of tau pathology in Alzheimer's Disease | |
| CA2986891C (en) | Compositions for use in treating parkinson's disease and related disorders | |
| JP2022058446A (en) | Formulations of l-ornithine phenylacetate | |
| JPWO2013118773A1 (en) | Preventive or therapeutic agent for idiopathic inflammatory myopathy | |
| JP2018531929A5 (en) | ||
| JP7148629B2 (en) | Chinese herbal composition for preventing and/or treating ischemia reperfusion injury | |
| KR101401744B1 (en) | Pharmaceutical composition for treating anxiety disorder, containing n-acetyl-l-cysteine or derivative thereof | |
| WO2009003694A3 (en) | Method for treating diseases related to mitochondrial dysfunction | |
| US20200197343A1 (en) | Compositions and methods for treatment of inflammation | |
| AU2017261303A1 (en) | Ophthalmic compositions | |
| US10537531B2 (en) | Casein coated drug-loaded iron oxide nanoparticles | |
| Gold | Efficacy and tolerability of a fixed combination of clindamycin phosphate (1.2%) and benzoyl peroxide (3.75%) aqueous gel in moderate and severe acne vulgaris subpopulations | |
| KR101891395B1 (en) | Pharmacedual composition for preventing or treating ototoxicity by additional effect of cisplatin | |
| CN104997771A (en) | Use of compound P7C3-A20 in preparation of drug for treating cerebral ischemic diseases | |
| RU2506950C2 (en) | Combination of carbostyril and carnitine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |